Nursing care
Insulin Lispro: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Insulin lispro is a rapid-acting insulin analogue with onset in about 15 minutes, peak at 30 to 90 minutes, and duration of 3 to 5 hours. Because it works so fast, the meal tray must be in front of the patient before you inject it. Give it and walk away and the patient can be hypoglycaemic before the food arrives.
Why this drug and not another
Insulin lispro is chosen when a patient needs insulin coverage that matches the speed of a meal, not the slow curve of a basal dose. Its molecular structure, with the positions of proline and lysine reversed, stops it clumping into hexamers the way regular human insulin does. It gets into the bloodstream faster because of that, which is the entire clinical point of the drug.
This matters on the ward because timing decisions change depending on which insulin is in the syringe. Regular insulin gives you a 30-minute window to sort out the tray, check labs, or deal with an interruption. Lispro does not give you that window. If a prescriber has ordered lispro instead of regular insulin, it is almost always because they want tighter, faster postprandial control, often in a patient using multiple daily injections or an insulin pump.
Administration and timing
The single fact that governs safe administration is the 15-minute onset. The meal tray must be in front of the patient, and the patient must be able and willing to eat, before you give the injection. Giving lispro and then leaving to fetch the tray, wait for a delivery, or finish another task is how patients end up hypoglycaemic before they have taken a bite.
Give it subcutaneously, rotating sites between the abdomen, thigh, upper arm and buttock to avoid lipohypertrophy. It can also be given via continuous subcutaneous infusion in insulin pumps and by IV push or infusion in critical care under close glucose monitoring, though the subcutaneous premeal route is what you will use most often on a general ward. Never administer it more than 15 minutes before a meal without confirming the patient is genuinely about to eat.
Monitoring parameters
Check blood glucose immediately before administration, since the dose is often adjusted against that reading using a sliding scale or correction factor. Recheck postprandially per unit protocol, and again before the next scheduled dose so any trend toward hypoglycaemia or hyperglycaemia is caught early.
Watch for signs of hypoglycaemia in the first one to two hours after the dose, when the drug is at or near peak action: tremor, diaphoresis, tachycardia, confusion, and in severe cases loss of consciousness. In a patient who cannot report symptoms, such as someone sedated or with cognitive impairment, rely on scheduled glucose checks rather than symptom reporting alone.
Adverse effects to report
Hypoglycaemia is the adverse effect that matters most because of how fast this drug acts. Report a blood glucose below the threshold set by unit policy, typically around 70 mg/dL, along with any neurological or autonomic symptoms, so the prescriber or protocol-driven treatment can respond immediately.
Injection site reactions, including redness, swelling or lipodystrophy from repeated use of the same site, should be reported and documented, as should any signs of an allergic reaction such as urticaria, angioedema or, rarely, anaphylaxis. Persistent hyperglycaemia despite dosing also needs escalation, since it can signal insulin resistance, illness, or a problem with the delivery device in a patient using a pump.
Contraindications and cautions
Insulin lispro is contraindicated during episodes of hypoglycaemia and in patients with known hypersensitivity to the drug. Use caution in renal or hepatic impairment, where insulin clearance is reduced and the risk of prolonged hypoglycaemic effect increases even though onset and peak timing stay similar.
Hypokalaemia is a real risk because insulin drives potassium into cells, so monitor serum potassium in patients receiving IV insulin therapy or those with existing electrolyte imbalance. Beta-blockers can mask the tachycardia and tremor that usually warn a patient of hypoglycaemia, so patients on these drugs need closer glucose monitoring rather than reliance on symptoms.
Teaching points the exam tests
NCLEX-style questions on lispro almost always hinge on timing: the correct answer has the patient eating within 15 minutes of the injection, not 30, and not whenever a tray happens to arrive. Expect a question that describes a nurse giving the injection and then getting pulled away, with the correct response being to have confirmed the meal was ready first.
Teach patients to check blood glucose before injecting, to have food available at the bedside or table before the needle goes in, and to recognise early signs of hypoglycaemia. Teach injection site rotation and proper storage: unopened vials or pens are refrigerated, while an in-use pen is kept at room temperature and discarded after the manufacturer's stated time, commonly 28 days.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our endocrine practice questions are the closest set to what this page covers.
Common questions
How fast does insulin lispro start working?
Onset is around 15 minutes, with peak effect between 30 and 90 minutes and duration of roughly 3 to 5 hours. This is why the meal must be ready before you administer it, not after.
Can insulin lispro be given IV?
Yes, it can be given by IV push or infusion in critical care settings under close glucose monitoring, in addition to the more common subcutaneous route.
What is the difference between lispro and regular insulin for timing?
Regular insulin is given 30 minutes before a meal because it acts more slowly. Lispro is given within 15 minutes of eating because its onset is much faster, so the timing window is tighter and less forgiving.
What do I do if a patient's meal tray is delayed after I've given lispro?
Notify the team immediately and monitor blood glucose closely; the patient may need a fast-acting carbohydrate source on standby. This scenario is exactly why the tray should be confirmed present before the injection is given, not after.